Cytokines, such as GM-CSF, IL-2, IL-12, and IFN-α, play very important roles in cancer treatment, but cytokines generally have short half-lives, act over short distances, and need to be repeatedly administered in short intervals to maintain efficient bioavailability, which limits their widespread clinical use. This evidence concerns the gene IFNA1 and cancer.